angiotensin antagonist, by blocking this negative feedback of AII, stimulates renin release in normal and sodium-depleted rats, dogs, rabbits and man.1) Since saralasin-induced renin release is inhibited by the beta-adrenergic blocking agent, propranolol, some functional connections between the sites of action of AII and the sympathetic nervous system in the juxtaglomerular cells have been proposed. 2) The present study was undertaken to evaluate further the possible interaction of AII with the sympathetic nervous system with regard to renin release. First, the effect of propranolol on the release of renin induced by an angiotensin converting enzyme inhibitor, captopril, was examined in conscious rats. Secondly, the effect of AII on renin release stimulated by the beta agonist isoproterenol was investigated, also in conscious rats.
METHODS
Male Wistar rats weighing 250-350Gm were used in this study. They were fed a regular rat chow containing 104mEq/Kg of sodium and 177mEq/Kg of potassium. AII rats were anesthetized with ether. A venous catheter was placed in the jugular vein and an arterial catheter was introduced into the carotid artery. Both catheters, filled previously with 0.9% saline containing heparin 100U/ml, were tunnelled subcutaneously to exit from the skin between the scapulae. Following the surgical procedure, all rats were allowed to recover for 24 hours.
We performed a preliminary experiment in individual rats to examine the effect of blood replacement immediately following blood sampling on plasma renin activity (PRA), blood pressure and heart rate, since blood sampling in small animals could lead to a decrease in blood volume and influence these parameters. Blood pressure and heart rate were recorded on a Nihon-Kohden multipurpose recorder through the arterial catheter connected to a pressure transducer. Two ml of blood were collected through the venous catheter renin activity in the renal venous plasma .3).4) AII can inhibit renin release from the nonfiltering kidney without producing detectable changes in renal blood flow or renal perfusion pressure. These observations have been interpreted as evidence of a direct effect of AII on the juxtaglomerular cells.
Further support for the direct negative feedback by endogenous All on renin release comes from experiments with the AII antagonist, saralasin,5) and the converting enzyme inhibitors, teprotide5) and captopril. In these experiments blockade of AII generation or of AII receptors led to an increase in PRA in the intact animals. Capponi et al6) demonstrated the inhibition of isoproterenol-stimulated renin release from rat kidney slices by both AII and a number of betaadrenergic blockers. They pointed to the possibility that AII may act directly on the juxtaglomerular cells via a beta-adrenergic mechanism. Moreover, in a clinical study with hypertensive patients, Pettinger et al2) showed that saralasin-induced renin release was prevented by the administration of propranolol. This observation also indicated that the inhibition of renin release by AII is somehow related to the adrenergic control of renin secretion.
In the present study captopril increased PRA in a dose-related manner. This increase in PRA provoked by captopril was presumably due to the interruption of the so-called "short-loop" negative feedback mechanism of AII on renin release since blood pressure was unaffected by captopril administration. Propranolol administered 20min following captopril injection definitely blunted the increase in PRA induced by captopril. This finding is in agreement with others.7),8) Although we cannot exclude the influence of the slight rise in blood pressure on renin release via the baroreceptor mechanism, these results strongly suggest possible connections between AII and the sympathetic nervous system in terms of renin release. It has been demonstrated that the addition of propranolol to captopril produces no further fall in blood pressure.8) However, propranolol may be useful in preventing the accumulation of large quantities of angiotensin I in plasma during long-term use of captopril. The rapid conversion of large quantities of accumulated angiotensin I could take place following discontinuation of captopril resulting in an abrupt elevation of blood pressure.9)
In our study AII infused in combination with isoproterenol did not inhibit the increase in PRA induced by isoproterenol. In contrast with our findings, Meyer et al10) and Vandongen et al11) found that the increase in PRA associated with isoproterenol infusion was markedly suppressed by simultaneous infusion of AII in rats. The latter authors interpreted their finding as evidence of a close functional relationship between the AII receptor and the beta-receptor in the kidney and proposed that the site of action of AII might be distal to the beta-receptor. It is noteworthy that this positional relationship is totally different from that which Pettinger et al2) proposed. They postulated that the AII receptor inhibiting renin release is functionally located proximal to the beta-adrenergic receptor mediating renin release. Our initial finding that propranolol inhibited the increase in PRA following captopril administration also supports the hypothesis that the AII receptor in the short-loop mechanism controlling renin release is functionally proximal to the beta-receptor mediating renin release. Our second finding that AII did not reduce the increase in PRA stimulated by isoproterenol neither refutes nor supports this hypothesis. The fact that we used a much smaller dose of AII relative to that of isoproterenol than did previous investigators might explain the discrepancy between our results and theirs.10),11) However, our second finding may indicate that beta-adrenergically mediated renin secretion and the AII short-loop feedback mechanism are independent.
Clarification of the relation between the AII receptor and the betareceptor with regard to renin release will require the use of a pure juxtaglomerular cell preparation and a better definition of the pharmacologic properties of receptors for AII and beta-adrenergic agonists on these cells.12)
